Antisoma Research
11
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
18.2%
2 terminated/withdrawn out of 11 trials
75.0%
-11.5% vs industry average
9%
1 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia
Role: lead
A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML)
Role: lead
Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study
Role: lead
Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia
Role: lead
A Phase II Study of AS1411 in Renal Cell Carcinoma
Role: lead
Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
Role: lead
Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer
Role: lead
Study of AS1411 in Advanced Solid Tumours
Role: lead
Phase I Safety Study of DMXAA in Refractory Tumors
Role: lead
Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
Role: lead
Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer
Role: lead
All 11 trials loaded